Myrcludex B had an update - how to understand it?

[ShawshankHK]

Mycludex B developer Hepatera had an update on its website, dated Feb 14, about Mycludex. The news is in Russian language only as of now. I translated using google translate, attached below.

Please someone who's following their progress explain a bit about how to read this news? Is this just an "on track" update? Does it provide any more information that some guys here used to argue about like dose amount? etc..

Thanks!

http://www.hepatera.ru/news

February 14, 2014
GEPATERA COMPLETED THE INCLUSION OF ALL PATIENTS WITH CHRONIC HEPATITIS B IN PHASE IIA CLINICAL STUDY
Russian biotechnology company set Gepatera completed all scheduled patients in clinical trial phase IIa Mirkludeks B (Myrcludex B), aimed at investigating the efficacy and safety in patients with chronic hepatitis B.

Gepatera company, established in 2011 and invested venture fund Maxwell Biotech, created with the participation of RVC capital, engaged in the development of the drug for the treatment of chronic viral hepatitis B and D Mirkludeks B together with the German biotech company MYR GmbH, a portfolio company of one of the largest European venture capital funds High -Tech Gründerfonds.

In a clinical Phase IIa study investigated the safety, tolerability and efficacy of multiple doses of the study drug in comparison with the control group receiving standard therapy with nucleoside analogs. Particular attention is paid to the effectiveness of the parameters, which in most cases, existing treatment regimens do not affect.

In specialized clinical centers in Moscow, St. Petersburg, Chelyabinsk, Samara Stavropol and included 48 patients. Preliminary results of the study are expected by June 2014 and will subsequently be presented at international professional conferences.

Bogomolov Pavel, Head of Department of Hepatology BWW MONICA named after MF Vladimir, head of the Moscow Regional Hepatology Centre, Ministry of Health chief hepatologist Moscow Region, said: "We are pleased that we were able to complete patient enrollment in this important for hepatology study which looked expect not only world leaders in science and medicine for chronic hepatitis, but thousands of Russian and foreign patients. "

Chronic hepatitis B is a serious problem to be faced health systems worldwide. According to the World Health Organization, about 400 million people suffer from chronic forms of the disease. Market therapy for chronic hepatitis B is increasing every year, but it remains unsaturated, and maintains a high growth potential.

Alexander Alexandrov, medical director of Maxwell Biotech Group commented: "The inclusion of all patients in the planned Phase IIa clinical trial is an important milestone for the company and the product, the success of which can change the international standards for the treatment of chronic hepatitis B».

[makeadifferencenow]

I spoke with them early Jan they said they had completed the enrollment process

[HK_1966]

Seems like just done with the enrolment.

Next step, the actual trial?

[Rome70]

Google translation is not too bad. There is nothing else between the lines.